Mounjaro vs Ozempic: Which Works Better for Weight Loss? | TODS Bangalore

GLP-1 vs Dual GLP-1/GIP Therapy

Mounjaro vs Ozempic

Which Works Better for Weight Loss?

A real, clinically grounded comparison of Tirzepatide vs Semaglutide — mechanism, trial data, outcomes, costs, and who each medication suits best. From the specialist team at TODS, Bangalore.

📅 Book Your Consultation 💬 WhatsApp Us

20.9%

Mounjaro
avg weight loss

Mounjaro vs Ozempic Weight Loss Comparison

14.9%

Ozempic
avg weight loss

The Clinical Question

Making an Evidence-Based Choice

"Should I take Mounjaro or Ozempic?" is one of the most common questions we hear from patients considering medical weight loss at TODS. It is an excellent question — and one that deserves a real, clinically grounded answer rather than a marketing slogan.

Both Mounjaro (Tirzepatide) and Ozempic (Semaglutide) are GLP-1-based therapies with robust clinical evidence behind them. Both have transformed how obesity medicine works in practice. But they are not identical, and the differences matter — both in terms of mechanism and in terms of which medication is better suited to a given patient.

This article gives you a complete, doctor-informed comparison so that when you sit down with your TODS physician, you are equipped to have a meaningful conversation about which treatment is right for your specific health profile and goals.

⚖️

Quick Navigation

01 Understanding the Mechanism Difference 02 Clinical Trial Evidence: Head-to-Head 03 Weight Loss Outcomes: What to Realistically Expect 04 Side Effect Profiles Compared 05 Cost Comparison in India (2026) 06 Who Should Consider Mounjaro? 07 Who Should Consider Semaglutide? 08 The TODS Approach: Personalised Selection 09 Frequently Asked Questions 10 Doctor Review 11 Serving Bangalore & Nearby Areas 12 Book Your Consultation

The Science Explained

Understanding the Mechanism Difference

The most fundamental difference between Mounjaro and Ozempic is mechanistic — and it explains most of the clinical outcome differences.

Ozempic contains Semaglutide, a GLP-1 receptor agonist only. Mounjaro contains Tirzepatide, which is a dual agonist — it activates both GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously.

GIP is an incretin hormone that works synergistically with GLP-1 to improve insulin secretion, reduce glucagon release, and modulate fat storage. By targeting both pathways simultaneously, Tirzepatide produces a more comprehensive metabolic effect than GLP-1 agonism alone.

Think of it this way: if GLP-1 agonism is one lever for metabolic change, dual GLP-1/GIP agonism pulls two levers at once. The clinical outcome of this is reflected in the trial data.

Mounjaro (Tirzepatide)

Dual GLP-1 + GIP agonist — activates both incretin hormone pathways for superior metabolic effect, greater appetite suppression, and enhanced fat cell regulation.

Ozempic (Semaglutide)

GLP-1 receptor agonist only — activates a single but highly effective pathway with strong clinical evidence for weight loss and cardiovascular protection.

Shared Effects (Both Medications)

Slow gastric emptying, reduce appetite, improve insulin sensitivity, lower blood sugar, and produce meaningful weight loss with once-weekly self-injection.

Published Trial Data

Clinical Trial Evidence: Head-to-Head

The most direct evidence comes from SURPASS-2, which compared Tirzepatide directly against Semaglutide 1 mg. Tirzepatide demonstrated superiority at all doses tested.

🏆

20.9%

SURMOUNT-1 (Mounjaro)

Mean weight loss at 15 mg Tirzepatide over 72 weeks — the strongest weight loss data for any approved GLP-1 class medication to date.

NEJM, 2022

📊

14.9%

STEP-1 (Ozempic/Wegovy)

Mean weight loss at 2.4 mg Semaglutide over 68 weeks in non-diabetic patients — significantly superior to placebo (2.4%) with strong cardiovascular benefits.

NEJM, 2021

⚖️

SURPASS-2

Direct Head-to-Head

Tirzepatide at 5 mg, 10 mg, and 15 mg all demonstrated superior HbA1c reduction and weight loss vs Semaglutide 1 mg in T2D patients. Real-world data (JAMA) confirms this pattern.

Lancet, 2021

Parameter	Mounjaro Tirzepatide	Ozempic Semaglutide
Mechanism	Dual GLP-1 + GIP agonist Unique	GLP-1 agonist only
Max Approved Dose	15 mg weekly	2.4 mg weekly (Wegovy)
Peak Weight Loss (Trials)	~20.9% Higher	~14.9%
Cardiovascular Evidence	SURMOUNT-MMO ongoing	SELECT: 26% risk reduction Established
Injection Frequency	Once weekly	Once weekly
Administration	Subcutaneous pen	Subcutaneous pen
India Approval Status	Approved (T2D & obesity)	Ozempic (T2D); Wegovy (obesity)
Generic Availability	Limited (emerging)	Yes — multiple manufacturers More Options
GI Side Effects	Similar profile	Similar profile
Long-Term Safety Data	3+ years emerging	5+ years established More Data

Realistic Expectations

Weight Loss Outcomes: What to Realistically Expect

For Semaglutide (Ozempic/Wegovy) at maximum doses, most patients in supervised programmes can expect 10–15% body weight reduction over 12–18 months. Early responders (5%+ loss in first 12 weeks) tend to have the best long-term outcomes.

For Tirzepatide (Mounjaro), the expected range in well-supervised programmes is broadly 15–20% body weight reduction over 12–18 months at higher doses. Again, individual variation is significant, and no ethical provider can guarantee specific outcomes.

It is also important to note that both medications provide metabolic benefits — in blood sugar, blood pressure, lipids, and liver health — that extend well beyond the number on the scales. These functional improvements are often the most clinically meaningful outcome for patients with metabolic disease.

Mounjaro (Tirzepatide 15mg) ~20.9%

SURMOUNT-1 trial average — 72 weeks

Ozempic/Wegovy (Semaglutide 2.4mg) ~14.9%

STEP-1 trial average — 68 weeks

Placebo + Lifestyle ~2.4%

Control arm — lifestyle intervention only

Safety & Tolerability

Side Effect Profiles Compared

Both medications share a similar GI side-effect profile driven by the shared GLP-1 mechanism of slowing gastric emptying.

Shared Side Effects (Both Medications)

These are related to GLP-1 receptor activation and are most pronounced early in treatment and during dose increases. Gradual titration — standard in the TODS protocol — minimises their impact significantly.

🤢 Nausea — most common early, typically resolves within 2–3 weeks

🔄 Constipation or diarrhoea — manageable with dietary adjustments

😴 Reduced appetite, occasional fatigue or headache

⚠️ Rare serious: pancreatitis, gallbladder disease, thyroid C-cell concerns

Mounjaro-Specific Note

Discontinuation rates were slightly higher in some Tirzepatide trial arms — not because it is harder to tolerate for most patients, but because the titration schedule must be followed carefully. This is standard practice at TODS and is actively managed during follow-up appointments.

📋 Careful titration schedule essential

🩺 Regular monitoring by TODS physicians reduces discontinuation risk

Shared Contraindications

Neither medication should be used in patients with personal or family history of medullary thyroid carcinoma (MTC) or MEN2 syndrome, pregnancy, or severe GI disease.

Pricing in India

Cost Comparison in India (2026)

Cost is a practical reality. As of mid-2026, both medications are available at varying price points — with generic Semaglutide making GLP-1 therapy increasingly accessible.

💛

Mounjaro

Tirzepatide (Eli Lilly)

Starter dose (2.5 mg/month) ~₹13,125/month

Per injection (2.5 mg) ~₹3,281

Maximum dose (15 mg/month) ~₹25,781/month

Generic Tirzepatide Emerging — discuss at consult

Higher cost than Semaglutide options, but often preferred by patients seeking maximum average efficacy. Full cost transparency at your TODS consultation.

❤️

Ozempic / Wegovy

Semaglutide (Novo Nordisk)

Ozempic per injection ~₹1,415

Wegovy starter (0.25 mg/month) ~₹5,660/month

Generic Semaglutide per injection ~₹325

Price reduction (Apr 2026) Up to 48% lower

For patients where cost is a primary constraint, Semaglutide — particularly generic options — offers meaningful weight loss at significantly lower cost. Excellent choice for long-term affordability.

Personalised Prescribing

Who Should Consider Which Medication?

The right medication is determined by your medical profile, not by which has a better marketing campaign.

💛

Consider Mounjaro

Tirzepatide (Eli Lilly)

✓ Type 2 diabetes + obesity — dual glucose-lowering and weight-loss mechanism offers compounded benefit

✓ Maximising expected weight loss — well-informed patients wanting strongest average trial outcomes

✓ Inadequate response to Semaglutide — patients who tried Ozempic with insufficient results

✓ Metabolic syndrome — cluster of high blood sugar, blood pressure, triglycerides, and central obesity

✓ Higher budget available — patients for whom cost is not a primary constraint

❤️

Consider Semaglutide

Ozempic / Wegovy (Novo Nordisk)

✓ First-line choice for most patients — longer track record, more published long-term safety data

✓ Established cardiovascular disease — SELECT trial shows 26% reduction in major CV events, a specific evidence base not yet matched by Tirzepatide

✓ Cost-conscious patients — generic options from ₹325/injection make therapy accessible

✓ Preference for more data — patients who value the broader published evidence base

✓ PCOS + insulin resistance — increasingly discussed as beneficial for metabolic and reproductive outcomes

Our Medical Philosophy

The TODS Approach: Personalised Selection

We do not have a default recommendation at TODS. The right medication is determined by your medical profile — your BMI, comorbidities, medications, cardiovascular history, glycaemic status, financial situation, and treatment goals.

A 10-minute online quiz cannot make this decision. A thorough physician consultation can. Our initial assessments are comprehensive and unhurried. We want patients to leave their first appointment with a clear understanding of their options, realistic expectations, and a treatment plan they understand and feel confident in.

Comprehensive Medical Assessment

Full metabolic panel, body composition, cardiovascular risk, thyroid function, and medication review to establish your baseline profile.

Personalised Drug Selection

Evidence-based discussion of Mounjaro vs Ozempic/Wegovy based on your clinical profile, goals, and financial situation — no one-size-fits-all approach.

Supervised Titration & Monitoring

Careful dose escalation with regular physician check-ins to optimise efficacy and manage any side effects during treatment.

Lifestyle Anchoring & Exit Planning

We build sustainable habits throughout treatment and plan for medication tapering — because what happens after treatment matters as much as what happens during it.

Common Questions

Frequently Asked Questions

Q: Is Mounjaro always better than Ozempic for weight loss?

On average, Tirzepatide produces greater weight loss than Semaglutide in clinical trials. But 'better' depends on individual factors — cardiovascular history, cost, diabetes status, and prior treatment response all matter. A physician consultation is the only way to determine which is more appropriate for you.

Q: Can I switch from Ozempic to Mounjaro?

Yes, switching is possible but should be done under medical supervision with appropriate dose management. There is no established direct conversion dose, so your TODS physician will guide this transition safely with a restart titration protocol.

Q: Which has fewer side effects — Mounjaro or Ozempic?

Both have similar GI side effect profiles. Side effect management depends heavily on proper dose titration, which is a core component of the TODS programme. Neither is clearly superior in tolerability for most patients when titrated correctly.

Q: Does TODS prescribe both Mounjaro and Ozempic?

Yes. We prescribe both as part of our GLP-1 weight loss programme, based on each patient's clinical profile and preferences. We also prescribe Wegovy and generic Semaglutide where appropriate.

Q: Can I take both Mounjaro and Ozempic at the same time?

No. These medications should not be used concurrently. Only one GLP-1/dual agonist therapy is prescribed at a time. Combining them provides no additional benefit and increases the risk of adverse effects significantly.

Q: Where in Bangalore can I get a Mounjaro or Ozempic consultation?

At TODS, located in South Bangalore and easily accessible from Koramangala, HSR Layout, JP Nagar, Electronic City, and surrounding areas. We offer both in-clinic and telemedicine consultations.

⚕️

Medical Review Notice

Clinical Accuracy Verified

This comparison has been reviewed by the TODS medical team for clinical accuracy. All clinical data cited reflects published peer-reviewed trial findings including SURMOUNT-1, STEP-1, SURPASS-2, and the SELECT trial. Information reflects the current regulatory status of Mounjaro and Ozempic/Wegovy in India as of mid-2026. This content does not constitute personalised medical advice. Treatment decisions are always individualised and should be made in consultation with a qualified physician.

Reviewed by: Dr. Tulip, MS, FMAS, FIAGES

Senior Bariatric & Metabolic Surgeon | Specialist in Obesity Medicine, Bariatric Surgery, Metabolic Health | TODS India, Bangalore

Serving Bangalore

TODS: Locally Accessible, Medically Rigorous